BioSpecifics Technologies Corp.
http://www.biospecifics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From BioSpecifics Technologies Corp.
Deal Watch: AbbVie Offloads Three Cystic Fibrosis Candidates To Sionna
Plus deals involving Abeona/Beacon, TuHura/Kintara, Crosswalk/Codexis, Lantheus/Life Molecular Imaging as well as tech transfer agreements and small deals involving Pfizer, Sanofi and Ipsen.
Legend Buyout Report Boosts, Validates China Biotech
A reported buyout bid for Legend Biotech has delivered a much needed shot of confidence to the Chinese biotech sector, despite not being confirmed. Amid a shifting environment, Hengrui also sees globalization as essential to its future.
M&A Activity During Q2 Declined In Volume And Valuation
Following a pair of $10bn+ deals in Q4 2023 and a $16.5bn takeout in Q1, the second quarter saw no acquisition priced as high as $5bn, Evaluate notes. Aggregate deal volume and values dropped from Q1.
The Scrip Awards Podcast, Episode 1: Genmab: The Ongoing Evolution Of Europe’s Antibody Powerhouse
A new podcast series marking 20 years of the Scrip Awards and their recognition of biopharma sector innovation.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice